Country / Region
APAC
Tags
Clinical Practice, Data analytics, Data quality, Genomics, Innovation, Research
Te Aho o Te Kahu (Cancer Control Agency) in collaboration with Health New Zealand - Te Whatu Ora in New Zealand is designing national standards for sharing cancer data across the healthcare system. This presentation will focus on the molecular and immunohistochemistry aspects of this work, which support the sharing of ancillary study results from the pathology labs to medical oncologists, haematologists, and radiation oncologists. These test results are crucial in supporting the diagnosis and treatment of cancer patients. We will describe our unique approach to modelling these genetic test results that supports the appropriate level of detail required by both structured pathology reports and cancer treatment clinicians.
Description
CanShare is a national project, developed by Te Aho o Te Kahu (Cancer Control Agency) in collaboration with Health New Zealand - Te Whatu Ora in New Zealand, to share cancer data using SNOMED CT and HL7 FHIR. The CanShare team is developing SNOMED CT enabled datasets to collect and share cancer data, including structured pathology requests and reports, genetic testing, surgical notes, systemic anti-cancer therapy, radiation oncology treatment, cancer registries, screening and more.
Scope
SNOMED CT was selected for a number of reasons. Firstly it is both a New Zealand national standard and an international standard. Secondly, it is the only terminology with the breadth and depth to standardise the wide range of cancer data that needs to be shared. Thirdly, SNOMED CT's semantic definitions enable advanced use of the data, including data reuse, data analytics and clinical decision support.
How SNOMED CT will be used
SNOMED CT value sets have been developed for a range of cancer-related data, including cancer types, morphologies, body sites, observables, test results, cancer grading, staging, prognostic factors, scoring, treatment intents, disease responses, and more. Observable entity and clinical finding templates are used to author new, fully defined molecular and immunohistochemistry tests and results (respectively). This includes gene mutations, gene amplifications, genetic rearrangements and mismatch repair deficiency.
Our use of SNOMED CT is driven by clinical use cases, including sharing structured pathology reports, systemic anti-cancer therapy care plans, radiation oncology treatment and surgical notes. SNOMED CT is being used as:
* A reference terminology to integrate data from different data silos and share clinical information between healthcare providers.
* An interface terminology in vendor systems (using the CanShare language reference set), and
* A source of semantic definitions for data analytics (using ECL queries on the New Zealand Health Terminology Service, NZHTS).
Why SNOMED CT will be used
Contact
